Kalaris Therapeutics, Inc.
KLRS
$3.48
-$0.06-1.70%
NASDAQ
| 03/31/2024 | |||||
|---|---|---|---|---|---|
| Net Income | 1.84% | ||||
| Total Depreciation and Amortization | -- | ||||
| Total Amortization of Deferred Charges | 13,116.67% | ||||
| Total Other Non-Cash Items | 30.00% | ||||
| Change in Net Operating Assets | -159.18% | ||||
| Cash from Operations | -9.31% | ||||
| Capital Expenditure | -- | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | -- | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | -- | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -76.40% | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | -104.27% | ||||
| Cash from Financing | -4.08% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | -24.42% | ||||